Emergent BioSolutions Inc., a specialty biopharmaceutical company, offers specialized products to healthcare providers and governments to address medical needs and emerging public health threats. Divisions The company has two operating divisions, Biodefense and Biosciences. Biodefense This division is a specialty biopharmaceutical business focused on countermeasures that address public health threats, specifically chemical, biological, radiological, nuclear and explosives threats, as well as emerging infectious diseases (EID). The U.S. government is the primary purchaser of the company’s Biodefense products and often provides it with substantial funding for the development of its Biodefense product candidates. The company’s Biodefense portfolio consists of five revenue generating products and various investigational stage product candidates. The company’s Biodefense division marketed products include BioThrax (anthrax vaccine adsorbed), the vaccine licensed by the U.S. Food and Drug Administration (the FDA), for the general use prophylaxis and post-exposure prophylaxis of anthrax disease; Anthrasil (anthrax immune globulin intravenous (human)), a polyclonal antibody therapeutic licensed by the FDA for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine), a heptavalent therapeutic licensed by the FDA for the treatment of botulinum disease; VIGIV (vaccinia immune globulin intravenous (human)), a therapeutic licensed by the FDA to address adverse events from smallpox vaccination; and RSDL (reactive skin decontamination lotion kit), a device cleared by the FDA for the removal or neutralization of chemical agents, T-2 toxin and various pesticide-related chemicals from the skin. The company’s Biodefense division investigational stage product candidates include NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant), a next generation anthrax vaccine; UV-4B, a novel antiviral being developed for dengue and influenza infections; GC-072, a primary compound in the EV-035 series of spectrum antibiotics, being developed for Burkholderia pseudomallei; VAX161C, a recombinant pandemic influenza vaccine candidate being developed by VaxInnate, Inc. and for which the company has an exclusive license agreement to manufacture and sell in the event of a surge order from the Biomedical Advanced Research and Development Authority (BARDA); PreviThrax (recombinant protective antigen anthrax vaccine, purified), an anthrax vaccine; and other Biodefense product candidates focused on public health threats and EID. The company has responded to specific Task Order Requests issued by BARDA for the development and manufacture of specific countermeasures as part of its Center for Innovation in Advanced Development and Manufacturing program focused on imminent public health threats, including pandemic influenza and Ebola. The company’s Biodefense division also includes multiple platform technologies, including the MVAtor (modified vaccinia virus Ankara vector) platform technology and Emergard, a military-grade auto-injector device designed for intramuscular self-injection of antidotes and other emergency response medical treatments that could address exposure to certain chemical agents and other similar emerging threats. Marketing and Sales The company markets and sells its Biodefense products to the U.S. government and domestic non-government organizations with a small, specialized marketing and sales group. Biosciences This division is a specialty biopharmaceutical business focused on therapeutics primarily in hematology/oncology with secondary areas of focus in transplantation, infectious disease and autoimmunity. The company’s Biosciences portfolio consists of four revenue-generating products, all of which were acquired through its acquisition of Cangene Corporation in 2014, as well as various investigational stage product candidates and a contract manufacturing services business. The company’s Biosciences division marketed products include IXINITY [coagulation factor IX (recombinant)], approved by the FDA for the prevention of bleeding episodes in people with hemoph
emergent biosolutions inc (EBS:New York)
400 Professional Drive
Gaithersburg, MD 20879
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for EBS.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.